Global Clinical Next-generation Sequencing Market 2022 - Snapshot

September 2022 | 54 pages | ID: GA8FF1A271ECEN
Gen Consulting Company

Abstracts

The global clinical next-generation sequencing market is anticipated to increase by USD 18 billion till 2028 at an average annual growth of 23.4 percent as per the latest report by Gen Consulting Company.

This industry report offers market estimates of the global market, followed by a detailed analysis of the component, disease class, disease category, test complexity, test purpose, and region. The global market data on clinical next-generation sequencing can be segmented by component: instrument, workflow solution (kits, services, etc.). Clinical next-generation sequencing market is further segmented by disease class: cancer, non-cancer. The non-cancer segment captured the largest share of the market in 2021. Based on disease category, the clinical next-generation sequencing market is segmented into: cardiovascular, clinical microbiology and infectious diseases, mendelian disorders, metabolic/immune, neurological, oncology, reproductive health, transplantation. According to the research, the oncology segment had the largest share in the global clinical next-generation sequencing market. On the basis of test complexity, the clinical next-generation sequencing market also can be divided into: hotspot, multi-gene, single gene, whole genome, whole/targeted exome. The multi-gene segment held the largest revenue share in 2021. Clinical next-generation sequencing market by test purpose is categorized into: diagnosis, monitoring, screening/early detection, therapy guidance. The clinical next-generation sequencing market by region can be segmented into: Asia Pacific, Europe, North America, Rest of the World (RoW).

The global clinical next-generation sequencing market is highly competitive. The key players in the clinical next-generation sequencing market include ANGLE plc, Becton Dickinson and Company, BGI Group, Biocept Inc., Biodesix Inc., Biolidics Limited, Bio-Techne Corporation, Burning Rock Biotech Limited, CareDx Inc., Danaher Corp., Epigenomics AG, Eurofins Scientific SE, EXACT Sciences Corporation, Fulgent Genetics Inc., GeneDx Inc., Guardant Health Inc., Illumina Inc., Koninklijke Philips N.V., Merck KGaA, Myriad Genetics Inc., NeoGenomics Laboratories Inc., Qiagen N.V., Quest Diagnostics Incorporated, Roche Holding AG, Thermo Fisher Scientific Inc.

The data-centric report focuses on market trends, status and outlook for segments. With comprehensive market assessment across the major geographies, the report is a valuable asset for the existing players, new entrants and the future investors.

Why buy this report?

• Get a detailed picture of the Global Clinical Next-generation Sequencing Market
• Identify segments/areas to invest in over the forecast period in the Global Clinical Next-generation Sequencing Market
• Understand the competitive environment, the market’s leading players
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.

Contents

PART 1. SUMMARY

PART 2. INTRODUCTION

Study period
Geographical scope
Market segmentation

PART 3. CLINICAL NEXT-GENERATION SEQUENCING MARKET OVERVIEW

PART 4. MARKET BREAKDOWN BY COMPONENT

Instrument
Workflow solution (kits, services, etc.)

PART 5. MARKET BREAKDOWN BY DISEASE CLASS

Cancer
Non-cancer

PART 6. MARKET BREAKDOWN BY DISEASE CATEGORY

Cardiovascular
Clinical microbiology and infectious diseases
Mendelian disorders
Metabolic/immune
Neurological
Oncology
Reproductive health
Transplantation

PART 7. MARKET BREAKDOWN BY TEST COMPLEXITY

Hotspot
Multi-gene
Single gene
Whole genome
Whole/targeted exome

PART 8. MARKET BREAKDOWN BY TEST PURPOSE

Diagnosis
Monitoring
Screening/early detection
Therapy guidance

PART 9. MARKET BREAKDOWN BY REGION

Asia Pacific
Europe
North America
Rest of the World (RoW)

PART 10. KEY COMPANIES

ANGLE plc
Becton, Dickinson and Company
BGI Group
Biocept, Inc.
Biodesix, Inc.
Biolidics Limited
Bio-Techne Corporation
Burning Rock Biotech Limited
CareDx, Inc.
Danaher Corp.
Epigenomics AG
Eurofins Scientific SE
EXACT Sciences Corporation
Fulgent Genetics Inc.
GeneDx Inc.
Guardant Health, Inc.
Illumina, Inc.
Koninklijke Philips N.V.
Merck KGaA
Myriad Genetics, Inc.
NeoGenomics Laboratories, Inc.
Qiagen N.V.
Quest Diagnostics Incorporated
Roche Holding AG
Thermo Fisher Scientific Inc.

PART 11. METHODOLOGY